Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2014-09-02 Director's Dealing
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-09-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically announces a corporate name change and stock symbol change effective on a future date. It includes a press release as an exhibit. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (2412 characters) and serves as an announcement of a corporate event rather than a detailed financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-08-27 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2014, reporting the submission of matters to a vote of security holders at the Annual Meeting. It details the voting results on director elections, auditor ratification, and amendments to the Certificate of Incorporation including a reverse stock split and company name change. The content is focused on official voting results from a shareholder meeting, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4130 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). The document is not a full annual report, earnings release, or management discussion, but specifically a report of voting outcomes. Hence, the correct classification is DVA with high confidence.
2014-08-14 English
PRIMARY DOCUMENT
Director's Dealing
2014-07-17 English
PRIMARY DOCUMENT
Director's Dealing
2014-07-17 English
PRIMARY DOCUMENT
Director's Dealing
2014-07-17 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.